Can Hydrogen Water Help COVID-19 Recovery? What the Largest Trial Found
This page summarizes published research for general education. It isn't medical advice and doesn't replace guidance from your doctor.
This is the largest randomized trial of hydrogen water ever conducted, run across multiple countries during the COVID-19 pandemic to test a specific, urgent question: could a cheap, safe antioxidant intervention keep mild COVID-19 from getting worse?
What the research looked at
Published in the Journal of Clinical Medicine in 2024, this phase 3, randomized, triple-blind, placebo-controlled trial (known as Hydro-COVID) enrolled 675 outpatients across French and Serbian sites with confirmed mild-to-moderate COVID-19. Participants started treatment within 5 days of symptom onset, drinking hydrogen-rich water or a placebo twice daily for 21 days. The primary endpoint was clinical worsening by day 14 — a composite measure including fatigue, breathing difficulty, hospitalization, oxygen therapy, or death.
What they found
Clinical worsening occurred in 46.1% of the hydrogen water group compared with 43.5% of the placebo group — essentially no difference (and numerically slightly worse with hydrogen water, though not a statistically meaningful gap). There was no interaction with age, COVID-19 variant, or vaccination status, and symptom resolution time and side effects were similar between groups.
What this means in practice
This is exactly the kind of large, well-designed, multi-site trial that should carry real weight, and the honest result is a clear null: hydrogen-rich water did not reduce clinical worsening in outpatients with mild-to-moderate COVID-19. That doesn't necessarily mean hydrogen has no biological effects elsewhere (the mechanism and smaller trials in this library point to real antioxidant activity), but it does mean it shouldn't be relied on as a treatment or preventive measure for COVID-19 specifically. Standard medical guidance remains the right source for managing COVID-19 illness.
